Gensight biologics announces initial results from new meta-analyses on visual outcomes with lumevoq® gene therapy at nanos 2024

Paris--(business wire)--regulatory news: gensight biologics (euronext: sight, isin: fr0013183985, pea-pme eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced initial results of new meta-analyses in leber hereditary optic neuropathy (lhon), which show those treated with lumevoq® (gs010; lenadogene nolparvovec) gene therapy experienced a rate of visual recove.
META Ratings Summary
META Quant Ranking